Hirotaka Watada
Juntendo University
562 Papers
2.6K Citations
Hirotaka Watada is an academic researcher from Juntendo University. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 67, co-authored 460 publications. Previous affiliations of Hirotaka Watada include Osaka University & University of California, San Francisco.
Chat about Author
Papers
Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Nasib Ervinna,Tomoya Mita,Eisuke Yasunari,Kosuke Azuma,Rica Tanaka,Satoshi Fujimura,Dewi Sukmawati,Takashi Nomiyama,Akio Kanazawa,Ryuzo Kawamori,Yoshio Fujitani,Hirotaka Watada +11 more
TL;DR: Results indicated that the anti-atherosclerotic effect of anagliptin is mediated, at least in part, through its direct inhibition of SMC proliferation and inflammatory reaction of monocytes.
Association of gut microbiota and inflammatory markers in obese patients with type 2 diabetes mellitus: post hoc analysis of a synbiotic interventional study
TL;DR: A post hoc analysis of a 24-week randomized controlled study using synbiotics to investigate the association between gut microbiota and inflammatory markers identified four bacterial species related to chronic inflammation and predictive markers in responders to synbiotic supplementation among obese patients with type 2 diabetes mellitus.
Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes.
Tomoya Mita,Yusuke Osonoi,Takeshi Osonoi,Miyoko Saito,Shiho Nakayama,Yuki Someya,Hidenori Ishida,Masahiko Gosho,Hirotaka Watada +8 more
TL;DR: Breakfast skipping is an independent lifestyle habit that is associated with persistently increased arterial stiffness in patients with T2DM, according to a multivariable linear mixed-effects model.
Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan.
Yui Yoshida,Kosuke Kashiwabara,Yosuke Hirakawa,Tetsuhiro Tanaka,Shinsuke Noso,Hiroshi Ikegami,Mitsuru Ohsugi,Kohjiro Ueki,Tomoya Mita,Hirotaka Watada,Daisuke Koya,Koki Mise,Jun Wada,Miho Shimizu,Takashi Wada,Yumi Ito,Ichiei Narita,Naoki Kashihara,Masaomi Nangaku,Yutaka Matsuyama +19 more
TL;DR: By testing eGFR yearly and identifying risk factors in the early phase of diabetes, this study can identify patients at high risk of developing end-stage renal disease.
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
Brenda Bongaerts,Suzanne V. Arnold,Bernard Charbonnel,Hungta Chen,Andrew Cooper,Peter Fenici,Marília B. Gomes,Linong Ji,Kamlesh Khunti,Mikhail Kosiborod,Jesús Medina,Antonio Nicolucci,Marina Vladimirovna Shestakova,Iichiro Shimomura,Fengming Tang,Hirotaka Watada,Wolfgang Rathmann +16 more
TL;DR: The DISCOVER study as discussed by the authors investigated the proportion of older patients (aged ≥ 65 years) who potentially received an inappropriately intensive treatment (HbA1c level) by using a hierarchical regression model.